Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival

Documenti analoghi

• Identification ofPSMD11as a novel cuproptosis‐ and immune‐related prognostic biomarker promoting lung adenocarcinoma progression
  di: Qiumin Huang, et al.
  Pubblicazione: (2024)
• The expression and role of SUZ12 in lung adenocarcinoma
  di: Xingsheng Hu, et al.
  Pubblicazione: (2024)
• Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study
  di: Shuai Liang, et al.
  Pubblicazione: (2024)
• A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations
  di: Li Wang, et al.
  Pubblicazione: (2024)
• The association of genomic alterations with PD‐L1 expression in Chinese patients with EGFR/ALK wild‐type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy
  di: Fangfang Liu, et al.
  Pubblicazione: (2024)